4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

University of California, San Francisco293 enrolled

Overview

The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.

Study Type

OBSERVATIONAL

Enrollment

293

Conditions

Corticobasal Degeneration (CBD)Corticobasal Syndrome (CBS)Cortical-basal Ganglionic Degeneration (CBGD)Progressive Supranuclear Palsy (PSP)Nonfluent Variant Primary Progressive Aphasia (nfvPPA)Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * No known history of neurological disease, or meet criteria for one of the following: Corticobasal Syndrome or Degeneration (CBS or CBD); Progressive Supranuclear Palsy (PSP); or Oligo- or Variant- Progressive Supranuclear Palsy (o/vPSP) * Needs a reliable study partner who has frequent contact with the participant, who is available to provide information about the participant, and who can accompany the participant to research visits as needed * Must be willing and able to undergo testing procedures, which include longitudinal follow-up visits * Must be able to walk five steps with minimal assistance Exclusion Criteria: * Significant neurological disease other than CBD, PSP, or a variant PSP syndrome. * Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or metal fragments or metal objects in the eyes, skin, or body * In the site investigator's opinion, inability to complete sufficient key study procedures, or some other equivalent assessment of impairment

Locations (8)

University of California, San Diego (UCSD)

San Diego, California, United States

University of California, San Francisco (UCSF)

San Francisco, California, United States

Johns Hopkins University

Baltimore, Maryland, United States

Harvard University - Massachusetts General Hospital

Charlestown, Massachusetts, United States

Mayo Clinic - Rochester

Rochester, Minnesota, United States

Columbia University

New York, New York, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Toronto

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

Tau-PET Brain Scan

Change from Baseline of Tau protein distribution in the brain.

Time frame: Baseline, 1-year, and 2-years.

Amyloid-PET Brain Scan

Presence of Amyloid in the brain at Baseline.

Time frame: Baseline

Brain Volume on MRI

Change from Baseline of brain tissue volume.